The first time a biotech founder says, “We should start preparing for an IPO,” it often sounds like optimism. Sometimes it is a reaction to momentum: a clean data readout, a wave of inbound interest, a rising sector. What comes next, if the company is serious, is less romantic. It is a year or more of building the kind of operational truth that public markets can live with.
Leen Kawas has spent her career at that intersection of science and scrutiny. She is the CEO of EIT Pharma and the co-founder and Managing General Partner of Propel Bio Partners. She also serves on the board of Inherent Biosciences. Earlier, she co-founded Athira Pharma and led the company through a 2020 IPO, with biographies noting more than $400 million raised around that milestone and its surrounding financings.
Her view of IPO readiness, paraphrased from how she describes building companies, starts with a correction: an IPO is not a finish line. It is a switch in accountability.
Readiness begins when the story becomes testable
In private biotech, a company can live on a narrative supported by early signals. In public biotech, the narrative has to survive quarterly dissection. Kawas’s operating posture, reflected in her leadership bios, emphasizes advancing clinical programs through late-stage development with a patient-focused orientation. Underneath that is an investor reality: the public market wants a thesis that can be measured.
IPO readiness means the company can answer, with discipline, what the product is, who it is for, what it replaces, what the evidence shows today, and what the next decision points will be. The goal is not hype. The goal is a map.
The data package is a product of the organization
Teams sometimes treat “data” as a discrete asset, something the science group produces and the finance group presents. Leen Kawas tends to frame execution as cross-functional, the way her board biography describes her experience spanning drug discovery, clinical methodology, regulatory strategy, commercialization, and financing. That blend matters because IPO readiness depends on consistency across functions.
A public investor does not only evaluate the Kaplan-Meier curve or the biomarker panel. They evaluate the system that produced it: protocol discipline, vendor oversight, data integrity, monitoring, and the internal competence to interpret uncertainty without overreaching.
If the company cannot run a clean trial, it cannot run a clean public company.
Governance is not paperwork, it is trust
Before the roadshow deck, there is board composition, committee structure, and decision hygiene. The market reads governance as an early warning system. When something goes sideways in biotech, it is often a clinical surprise, a safety signal, a manufacturing constraint, or an operational miss. What investors want to believe is that the company will surface the issue early, quantify it clearly, and respond in a way that protects the long arc.
Kawas’s current roles make her unusually sensitive to this. As an operator and investor, she sits near the questions that boards and public shareholders keep asking: what did management know, when did they know it, and what did they do next? IPO readiness means you can answer those questions without improvising.
The internal operating rhythm has to match public time
A biotech can be scientifically excellent and still fail at being public-ready. The reason is cadence. Public life is a recurring cycle of close processes, guidance discipline, disclosure controls, and communications that can withstand scrutiny.
Kawas’s experience taking a company public in 2020, as described in her bios, is tied to scaling the company through late-stage programs while raising substantial capital. That combination forces a new kind of internal rhythm: finance must be able to forecast burn with credibility, clinical must be able to forecast timelines with realism, and leadership must be able to communicate without drifting into performance.
IPO readiness means the company can keep its promises in public time.
Manufacturing and quality belong in the IPO conversation early
In biotech, the story is often told as science first, manufacturing later. Public markets do not always separate them. They want to understand supply risk, quality systems, tech transfer timelines, and what it will take to scale.
A leadership team that treats manufacturing as an afterthought usually pays for it when timelines tighten. IPO readiness means the company has a credible plan for how the product will be made, controlled, and delivered, with a quality mindset that can survive audits and partnerships.
IPO readiness is also emotional readiness
There is a quieter side to this that leaders do not always say out loud. Going public changes how people feel inside the company. It introduces volatility, external judgment, and a constant temptation to optimize for the short term.
Kawas’s biographies consistently highlight her commitment to supporting innovators and building ecosystems, through Propel Bio Partners and board work. Read as a leadership philosophy, it suggests she sees durability as the real goal. IPO readiness is the ability to protect the work and the people doing it, even while the market tries to pull attention toward the stock.
A biotech company is IPO-ready when the science is sound, the operations are repeatable, the governance is credible, and the story can be tested without collapsing. Kawas’s career sits close to that reality: building organizations that can carry innovation into environments where scrutiny is constant and capital is conditional.
Learn more about Leen Kawas in her interview with Principal Post:
https://www.principalpost.com/in-brief/leen-kawas